Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

17.16USD
2:37pm EDT
Change (% chg)

$0.17 (+1.00%)
Prev Close
$16.99
Open
$17.08
Day's High
$17.33
Day's Low
$17.03
Volume
2,556,705
Avg. Vol
2,976,813
52-wk High
$51.61
52-wk Low
$15.22

Latest Key Developments (Source: Significant Developments)

NY A.G. Schneiderman, coalition of AGs expand investigation into opioid crisis
12:39pm EDT 

Sept 19 (Reuters) - New York A.G. Schneiderman::New York A.G. Schneiderman, bipartisan coalition of AGs expand multistate investigation into opioid crisis.Says served subpoenas to Endo International, Janssen Pharmaceuticals, Teva Pharmaceutical/Cephalon Inc and Allergan.Says Attorneys General have also served a supplemental investigative subpoena on Purdue Pharma.Attorneys General demanded information about distribution practices from AmerisourceBergen, Cardinal Health, McKesson.  Full Article

Teva and Nuvelution Pharma partner to accelerate development of Austedo tablets for use in Tourette Syndrome in the united states
10:00am EDT 

Sept 19 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva and Nuvelution Pharma partner to accelerate development of austedo® (deutetrabenazine) tablets for use in tourette syndrome in the united states.Teva Pharmaceutical Industries Ltd - upon fda approval of austedo® in ts, teva will pay nuvelution a pre-agreed return on its invested capital.Teva - ‍under terms of agreement, Nuvelution will fund and manage clinical development, driving all operational aspects of Phase III Program​.Teva Pharmaceutical Industries Ltd - ‍ under terms, Teva will lead regulatory process and be responsible for commercialization of austedo tablets​.  Full Article

Edge Therapeutics appoints Rosemary Crane to Board of Directors
7:00am EDT 

Sept 19 (Reuters) - Edge Therapeutics Inc :Edge Therapeutics appoints Rosemary A Crane, pharmaceutical industry leader, to its Board Of Directors.Edge Therapeutics Inc - ‍Crane's appointment expands Board of Directors to 10 members, eight of whom are independent​.Edge Therapeutics Inc - ‍Crane currently serves as a Director of Teva Pharmaceuticals and as vice chairman of Board of Zealand Pharma A/S​.  Full Article

Royal Unibrew CEO Jesper Jorgensen resigns
Monday, 18 Sep 2017 02:15pm EDT 

Sept 18 (Reuters) - Royal Unibrew A/S :Board of company and CEO Jesper B. Jorgensen have mutually agreed that Jesper B. Jorgensen resigns from his position.COO, Johannes F.C.M. Savonije will take over position as President & CEO of Royal Unibrew with effect as of Monday.Kare Schultz, has decided to retire from board of directors of Royal Unibrew with effect as of 1 January 2018.Royal Unibrew A/S - Board of directors has decided to appoint current deputy chairman of board of directors, Walther Thygesen, as chairman of board.Changes to board of directors will be effective as per 1 January 2018.  Full Article

Teva announces sale of remaining assets in women’s health portfolio for $1.38 bln
Monday, 18 Sep 2017 08:07am EDT 

Sept 18 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva announces sale of remaining assets in specialty global women’s health portfolio for $1.38 billion.Teva - ‍executes sale agreements for planned divestiture of global women's health business to generate total proceeds of $2.48 billion​.Teva - CVC Capital Partners fund VI to buy portfolio of products within co's global women's health business for $703 million in cash​.Teva-‍proceeds from sales, combined with proceeds from recent sale of paragard total $2.48 billion and will be used to progress repayment of term loan debt​.Teva Pharmaceutical Industries-‍foundation consumer healthcare to buy plan B One-Step, co's value brands of emergency contraception for $675 million in cash​.Teva Pharmaceutical - reinforcing "strategic focus" on CNS, respiratory as its core global therapeutic areas of focus within global specialty medicines​.Teva - ‍until transactions are completed, Teva will continue to market in normal course​ products involved in deals announced on Sept. 18.  Full Article

Teva receives FDA priority review for first line use of Trisenox
Tuesday, 12 Sep 2017 08:00am EDT 

Sept 12 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva receives fda priority review for first line use of trisenox® (arsenic trioxide) in patients with low to intermediate risk acute promyelocytic leukemia (apl).Teva Pharmaceutical Industries Ltd - ‍FDA has accepted SNDA for priority review with regulatory action expected in Q1 of 2018​.  Full Article

Cooper Companies announces agreement to acquire Paragard® IUD from Teva
Monday, 11 Sep 2017 04:15pm EDT 

Sept 12 (Reuters) - Cooper Companies Inc :The Cooper Companies announces definitive agreement to acquire Paragard® IUD from Teva.Cooper Companies Inc - boards of directors of both Cooper and Teva have unanimously approved transaction.Cooper Companies Inc - ‍excluding items, deal to be accretive to Cooper's gross and operating margins and about $0.70 to $0.75 accretive to EPS in year one​.Cooper Companies Inc - acquired business includes Teva's manufacturing facility in Buffalo, NY, which exclusively produces Paragard IUD.  Full Article

Teva announces sale of intrauterine contraceptive Paragard® to CooperSurgical
Monday, 11 Sep 2017 04:15pm EDT 

Sept 12 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva announces sale of Paragard® (intrauterine copper contraceptive) to CooperSurgical.Teva Pharmaceutical Industries Ltd - deal for ‍$1.1 billion cash transaction.​.Teva Pharmaceutical Industries Ltd - transaction includes Teva's manufacturing facility in Buffalo, NY, which produces Paragard® exclusively​.Teva - ‍continues to actively pursue additional divestiture opportunities, including sale of remaining assets of its global women's health business​.Teva Pharmaceutical Industries Ltd - ‍continues to actively pursue sale of its oncology and pain businesses in Europe​.Teva Pharmaceutical Industries Ltd - ‍until transaction is completed, Teva will continue to manufacture and sell Paragard® in U.S. in normal course​.Teva Pharmaceutical Industries Ltd - continues to expect to generate at least $2 billion in total proceeds from sale of these businesses.Teva Pharmaceutical Industries Ltd - continues to expect additional asset sales to be executed by year end 2017.  Full Article

Teva Pharmaceutical Industries's CEO Kåre Schultz will receive annual base salary of U.S.$2 mln‍​
Monday, 11 Sep 2017 06:51am EDT 

Sept 11 (Reuters) - Teva Pharmaceutical Industries Ltd ::Teva Pharmaceutical Industries - in connection with being named co's president, CEO, Kåre Schultz will receive annual base salary of U.S. $2 mln‍​.  Full Article

Incoming Teva CEO says new strategy to address restructuring, debt
Monday, 11 Sep 2017 05:10am EDT 

Sept 11 (Reuters) - Incoming CEO of Teva Pharmaceutical Industries Kare Schultz made following comments to Reuters::Says to develop new strategy to address "various restructuring initiatives" and Teva's "significant debt".."When I have physically joined Teva I expect that we will develop a joint strategy with the board and management and communicate that".."The strategy will of course have to address the various restructuring initiatives, of which some are already ongoing, and of course address the significant debt that the company has".."I can't give an exact time for when we will come with the strategy that explains how we will do it"..Schultz declined to give more detail on the potential split of the business..  Full Article

Photo

LPC: Banks line up €430m loan for CVC’s Teva asset buy

LONDON Three banks have lined up €430m of leveraged loans to back private equity firm CVC Capital Partners’ acquisition of the remaining assets in Teva Pharmaceutical Industries’ women’s health business, banking sources said.